Omada Health had its Relative Strength (RS) Rating upgraded from 68 to 71 Friday — a welcome improvement, but still short of the 80 or better score you look for.
When To Sell Stocks To Lock In Profits And Minimize Losses
This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the best stocks tend to have an RS Rating of above 80 as they launch their largest climbs. See if Omada Health can continue to show renewed price strength and hit that benchmark.
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock is able to establish and enter a buy zone in heavy trade.
The company showed 0% earnings growth last quarter, while sales growth came in at 49%.
Omada Health holds the No. 14 rank among its peers in the Medical-Services industry group. Hims & Hers Health, GeneDx Holdings and InfuSystem Holdings are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
